171920-15-3

Upstream product

• 4784-77-4 (E)-1-Bromo-2-butene 
• 5817-70-9 methyl N-benzylcarbamate 
• 100-46-9 benzylamine 

Downstream Products

• 107733-62-0 benzyl crotyl amine 
• 136784-14-0 diethyl N-{4-[2-(2-amino-3,4-dihydro-4-oxo-7-benzylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamate 
• 348620-51-9 2-amino-4-oxo-5-vinyl-7-benzyl-3,4,5,6-tetrahydropyrrolo[2,3-d]pyrimidine 
• 348620-33-7 1-benzyl-3-(methoxycarbonyl)-4-vinylpyrrolidin-2-one 
• 243636-59-1 N-benzyl-N-but-2-enyl-malonamic acid methyl ester 

Relevant academic research and scientific papers

A novel synthetic route to 7-substituted derivatives of the antitumor agent LY231514 (MTA)

This paper describes a further synthesis of the pyrrolo[2,3- d]pyrimidine antitumor agent MTA (LY231514). Manganic triacetate dihydrate- induced radical cyclization of methyl N-crotyl-N-(3',4'- dimethoxybenzyl)malonamide (4d) yielded the 3-carbomethoxy-2-pyrrolidinone 5d that was then thiated with P2S5 to the corresponding thiolactam (6d). Cyclization with guanidine gave the 7-substituted 2-amino-4(3H)-oxo-5,6- dihydro-pyrrolo[2,3-d]pyrimidine (7d). Pd-catalyzed coupling with diethyl 4- iodobenzoylglutamate yielded (in a single step) the diethyl ester 9d. Deprotection with H2SO4/TFA followed by saponification then gave MTA. Several additional 7-substituted derivatives of MTA were prepared by use of this methodology. In contradiction to a published claim, these 7-substituted derivatives proved to be devoid of any significant cell growth inhibitory activity.